Literature DB >> 25384365

Increased monocytic CD14⁺HLADRlow/- myeloid-derived suppressor cells in obesity.

Yi Bao1, Juanfen Mo1, Lingjuan Ruan1, Guo Li1.   

Abstract

Obesity is associated with numerous immunological disorders. The present study investigated the proportion and phenotype of myeloid‑derived suppressor cells (MDSCs) in the plasma of obese subjects and the association of these cells with the level of liver enzymes. Certain features of the immune response in obese subjects were examined by analyzing the expression of T cell receptor‑ζ (TCRζ) molecules on the surface of T cells. The expression and secretion of S100A9, a possible marker for MDSCs, were detected in the peripheral blood of obese subjects and compared with levels in lean controls. Results showed that the percentage of monocytic MDSCs, with the phenotype CD33+CD11b+CD14+HLADRlow/‑, was significantly increased in obese subjects compared with lean controls. The circulating level of monocytic MDSCs was positively correlated with the levels of liver enzymes in serum. The expression of the TCRζ molecule in the resting T cells was significantly lower in obese individuals than that of lean controls. The expression of S100A9 was detected in the majority of monocytes in peripheral blood mononulear cells, but no difference was identified in the frequency of CD14+S100A9+ cells between the obese and lean groups. However, the plasma level of S100A8/9 was significantly increased in obese compared with lean subjects. These observations suggested that the increased frequency of CD33+CD11b+CD14+HLADRlow/‑ cells may be responsible for the impaired T‑cell function and liver injury observed in obesity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384365     DOI: 10.3892/mmr.2014.2927

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  19 in total

Review 1.  Myeloid-Derived Suppressor Cells at the Intersection of Inflammaging and Bone Fragility.

Authors:  Keith L Kirkwood; Lixia Zhang; Ramkumar Thiyagarajan; Kenneth L Seldeen; Bruce R Troen
Journal:  Immunol Invest       Date:  2018-11       Impact factor: 3.657

2.  Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.

Authors:  Kimberly R Jordan; Puja Kapoor; Eric Spongberg; Richard P Tobin; Dexiang Gao; Virginia F Borges; Martin D McCarter
Journal:  Cancer Immunol Immunother       Date:  2017-01-20       Impact factor: 6.968

Review 3.  Implications of Inflammatory States on Dysfunctional Immune Responses in Aging and Obesity.

Authors:  Alyssa L Thomas; Pablo C Alarcon; Senad Divanovic; Claire A Chougnet; David A Hildeman; Maria E Moreno-Fernandez
Journal:  Front Aging       Date:  2021-09-22

Review 4.  Myeloid derived-suppressor cells: their role in cancer and obesity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Curr Opin Immunol       Date:  2018-03-13       Impact factor: 7.486

Review 5.  Obesity as an immune-modifying factor in cancer immunotherapy.

Authors:  Robert J Canter; Catherine T Le; Johanna M T Beerthuijzen; William J Murphy
Journal:  J Leukoc Biol       Date:  2018-05-15       Impact factor: 4.962

Review 6.  Myeloid-derived suppressor cells coming of age.

Authors:  Filippo Veglia; Michela Perego; Dmitry Gabrilovich
Journal:  Nat Immunol       Date:  2018-01-18       Impact factor: 25.606

Review 7.  Myeloid-derived suppressor cells (MDSC): When good intentions go awry.

Authors:  Maria Dulfary Sanchez-Pino; Matthew J Dean; Augusto C Ochoa
Journal:  Cell Immunol       Date:  2021-02-04       Impact factor: 4.868

Review 8.  MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.

Authors:  Chi Ma; Qianfei Zhang; Tim F Greten
Journal:  Cell Immunol       Date:  2021-01-21       Impact factor: 4.868

Review 9.  Obesity-Associated Myeloid Immunosuppressive Cells, Key Players in Cancer Risk and Response to Immunotherapy.

Authors:  Maria Dulfary Sanchez-Pino; Linda Anne Gilmore; Augusto C Ochoa; Justin C Brown
Journal:  Obesity (Silver Spring)       Date:  2021-02-22       Impact factor: 9.298

10.  Protective Effects of MitoTEMPO on Nonalcoholic Fatty Liver Disease via Regulating Myeloid-Derived Suppressor Cells and Inflammation in Mice.

Authors:  Jiayuan Wu; Li Zheng; Juanfen Mo; Xiujuan Yao; Chenliang Fan; Yi Bao
Journal:  Biomed Res Int       Date:  2020-07-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.